Objective: To assess the e ectiveness of the use of dexketoprofen, tamsulosin, silodosin, and tadala l in medical expulsive therapy for distal ureteral stones in male patients. Study Design: Cohort study. Place and Duration of Study: Department of Urology, Gazi Hospital, Samsun, Turkey, from March 2020 to March 2021. Methodology: Adult males satisfying the inclusion criteria were randomly assigned into dexketoprofen (Group 1), tamsulosin (Group 2), silodosin (Group 3), or tadala l (Group 4) treatment arms. The primary endpoint consisted of the stone expulsion rate at the end of four weeks, while the secondary endpoints were the expulsion rate after two weeks and the occurrence of adverse events. Clinical ndings were then compared among the study groups. Results: Altogether 193 patients, 50 (25.9%) in group 1, 48 (24.9%) in group 2, 49 (25.4%) in group 3, and 46 (23.8%) in group 4, were enrolled in the study. No signi cant di erence was determined in terms of age, body mass index, stone characteristics, expulsion time, pain episodes, or total analgesic consumption among the four groups. Expulsion rates in the fourth week were 48%, 79.2%, 81.6%, and 78.3% in groups 1, 2, 3, and 4, respectively. Stone expulsion rates were signi cantly greater in groups 2, 3, and 4 compared to group 1 (p <0.001), but no signi cant di erences were determined between groups 2, 3, and 4. No severe adverse e ects occurred throughout the study period. Conclusion: Tamsulosin, silodosin and tadala l exhibited higher expulsion rates for distal ureteral stones in male patients, although none was signi cantly superior to the others. All three are safe, e cacious, and well-tolerated, with only very minor side-e ects.